Patent US5116864A successfully refreshed from Google Patents.
US5116864A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for preventing restenosis following reconfiguration of body vessels
Assignee: Indiana University Research and Technology Corp
•
Filing: 1991-04-09
•
Granted: 1992-05-26
•
Expires: 2011-04-09
Abstract
Abstract Restenosis following vascular recanalization is prevented by administering a photoactivatable psoralen and, in conjunction with recanalization, delivering ultraviolet radiation to the region of said recanalization.
Inventors
- 👤 Keith L. March
- 👤 David R. Hathaway
- 👤 Robert L. Wilensky
- 👤 Brian L. Patton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 23:56
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/365; A61K31/366; A61K31/37; A61N; A61N5/00; A61N5/06; A61N5/0601; A61N5/0613; A61N5/062
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
76 words
A method for preventing restenosis in peripheral or cardiac vasculature following vascular recanalization which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing vascular recanalization said psoralen being administered in a safe and effective amount to achieve serum levels of psoralen appropriate for light-dependent inhibition of smooth muscle cell growth, (b) recanalizing at least a partially-occluded vessel, and (c) delivering ultraviolet radiation to the region of said recanalization in the presence of said psoralen.
Claim 2
Independent Claim
76 words
A method for preventing restenosis in peripheral or cardiac vasculature following vascular recanalization which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing vascular recanalization said psoralen being administered in a safe and effective amount to achieve serum levels of psoralen appropriate for light-dependent inhibition of smooth muscle cell growth, (b) recanalizing at least a partially-occluded vessel, and (c) delivering ultraviolet radiation to the region of said recanalization in the presence of said psoralen.
Claim 3
Dependent Claim
25 words
The method of claim 1 in which the psoralen is substituted at one or more of the 3, 4, 4', 5, 5' or 8 positions.
Claim 4
Dependent Claim
13 words
The method of claim 2 in which the substituents are methyl or methoxy.
Claim 5
Dependent Claim
11 words
The method of claim 3 in which the psoralen is 8-methoxypsoralen.
Claim 6
Dependent Claim
12 words
The method of claim 1 in which the psoralen is administered orally.
Claim 7
Dependent Claim
18 words
The method of claim 5 in which the ultraviolet radiation is from about 320 to about 400 nm.
Claim 8
Independent Claim
16 words
The method of claims 1-6 in which the sequence of steps (a) and (b) is reversed.
Claim 9
Independent Claim
79 words
A method for preventing restenosis following coronary angioplasty which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing coronary angioplasty said psoralen being administered in a safe and effective amount to achieve serum levels of psoralen appropriate for light-dependent inhibition of smooth muscle cell growth, (b) reconfiguring at least a partially-occluded coronary artery by coronary angioplasty, and (c) delivering ultraviolet radiation by fiber-optic means to the endoluminal surface of the artery in the region of said angioplasty.
Claim 10
Independent Claim
79 words
A method for preventing restenosis following coronary angioplasty which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing coronary angioplasty said psoralen being administered in a safe and effective amount to achieve serum levels of psoralen appropriate for light-dependent inhibition of smooth muscle cell growth, (b) reconfiguring at least a partially-occluded coronary artery by coronary angioplasty, and (c) delivering ultraviolet radiation by fiber-optic means to the endoluminal surface of the artery in the region of said angioplasty.
Claim 11
Dependent Claim
25 words
The method of claim 8 in which the psoralen is substituted at one or more of the 3, 4, 4', 5, 5' or 8 positions.
Claim 12
Dependent Claim
13 words
The method of claim 9 in which the substituents are methyl or methoxy.
Claim 13
Dependent Claim
11 words
The method of claim 10 in which the psoralen is 8-methoxypsoralen.
Claim 14
Dependent Claim
12 words
The method of claim 8 in which the psoralen is administered orally.
Claim 15
Dependent Claim
18 words
The method of claim 12 in which the ultraviolet radiation is from about 320 to about 400 nm.
Claim 16
Independent Claim
16 words
The method of claims 8-13 in which the sequence of steps (a) and (b) is reversed.
Claim 17
Independent Claim
70 words
A method for preventing restenosis in peripheral or cardiac vasculature following vascular recanalization which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing vascular recanalization, said psoralen being administered in an amount sufficient to achieve serum levels from about 0.1 to about 10 μM, (b) recanalizing at least a partially-occluded vessel, and (c) delivering ultraviolet radiation to the region of said recanalization in the presence of said psoralen.
Claim 18
Independent Claim
70 words
A method for preventing restenosis in peripheral or cardiac vasculature following vascular recanalization which comprises: (a) systemically administering a photoactivatable psoralen to a subject undergoing vascular recanalization, said psoralen being administered in an amount sufficient to achieve serum levels from about 0.1 to about 10 μM, (b) recanalizing at least a partially-occluded vessel, and (c) delivering ultraviolet radiation to the region of said recanalization in the presence of said psoralen.
Claim 19
Dependent Claim
25 words
The method of claim 15 in which the psoralen is substituted at one or more of the 3, 4, 4', 5, 5' or 8 positions.
Claim 20
Dependent Claim
23 words
The method of claim 16 in which the psoralen is selected from the group of 8-methoxypsoralen, 5-methoxypsoralen, 4-methylpsoralen, 4,4'-dimethylpsoralen, 4,5'-dimethylpsoralen, 4',8-dimethylpsoralen and 4,5',8-trimethylpsoralen.
Claim 21
Dependent Claim
29 words
The method of claim 15 in which the psoralen is 8-methoxypsoralen administered systematically in an amount sufficient to achieve serum levels of from about 0.1 to about 10 μM.
Claim 22
Independent Claim
18 words
The method of claims 15-18 in which the ultraviolet radiation is from about 320 to about 400 nm.
Claim 23
Independent Claim
16 words
The method of claims 15-18 in which the sequence of steps (a) and (b) is reversed.
References Cited (Backward Citations)
US4169204A
Cited
US4269851A
Cited
US4269852A
Cited
US4328239A
Cited
US4321919A
Cited
US4294822A
Cited
US4464354A
Cited
US4465691A
Cited
US4512762A
Cited
US4577636A
Cited
US4773899A
Cited
US4799479A
Cited
US4753958A
Cited
US4983625A
Cited
US4824436A
Cited
US4790315A
Cited
US4771777A
Cited
US4878492A
Cited
US4892519A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-05-26 | 1995-11-25 | 1996-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-05-26 | 1999-11-25 | 2000-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-05-26 | 2003-11-25 | 2004-05-26 | $7700.00 | Window Closed / Lapsed |